Can weight loss drugs boost heart function in obese heart failure patients?

NCT ID NCT06423599

Recruiting now Disease control Sponsor: Jens D Hove, MD,PHD Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares weight loss using semaglutide (a drug) versus a calorie-restricted diet in 100 people with obesity and heart failure with reduced ejection fraction. The goal is to see which approach better improves peak oxygen uptake, a measure of exercise capacity, after 52 weeks. Participants must be on stable heart failure medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Semaglutide
What this could lead to: If successful, this could show that weight loss with semaglutide improves exercise capacity and heart function in people with obesity and heart failure.
What could go wrong: This is a mid-stage trial with only 100 participants, so results may not apply to everyone. Semaglutide can cause side effects like nausea and vomiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congestive heart failure heart failure Obesity obesity disorder systolic heart failure Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEART FAILURE HEART FAILURE WITH REDUCED EJECTION FRACTION OBESITY WEIGHT LOSS

Contacts and locations

Locations

Amager and Hvidovre Hospital University of Copenhagen
RECRUITING

Copenhagen, DK-2650, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.